Document Detail

Antithrombotic therapy in the primary prevention of acute myocardial infarction.
MedLine Citation:
PMID:  2750673     Owner:  NLM     Status:  MEDLINE    
The high factor VII coagulant (VIIc) activity in men at high risk of coronary heart disease suggests that restoring normal hemostatic activity with appropriate oral anticoagulants might constitute effective primary prevention. A pilot study was therefore undertaken of a randomized, double-blind, placebo-controlled trial of long-term, low-dose warfarin therapy. Middle-aged men at high risk (mean VIIc 120% of standard) but without clinical coronary heart disease or contraindications to anticoagulants were randomized to warfarin or placebo. The initial warfarin dose (2.5 mg/day) was increased at intervals to lower VIIc to 70% of standard and increase the prothrombin time international normalized ratio to 1.6. The control participants received the same dose sequence of placebo. The pilot study confirmed the feasibility of the design, the absence of any increased risk of serious bleeding, and the high compliance and low withdrawal rate from randomized treatment. Accordingly, a full-scale thrombosis prevention trial has been launched, which, in addition to low-dose warfarin, includes a low-dose aspirin regimen (75 mg/day) in a factorial design. The aim of this trial is to produce a 30% reduction in coronary heart disease in 6,000 high-risk men aged 45 to 69 years. The men will receive either separate or combined therapy and will be followed up for 5 years. Evidence so far indicates that the risk of bleeding in those receiving combined therapy will be no higher than that in those taking aspirin alone.
G J Miller
Related Documents :
10753983 - Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adju...
20149073 - Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.
19560473 - Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The American journal of cardiology     Volume:  64     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1989 Jul 
Date Detail:
Created Date:  1989-08-25     Completed Date:  1989-08-25     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  29B-32B     Citation Subset:  AIM; IM    
Medical Research Council Epidemiology and Medical Care Unit, Northwick Park Hospital, Harrow, Middlesex, England.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aspirin / administration & dosage*,  adverse effects
Drug Administration Schedule
Drug Therapy, Combination
Hemorrhage / chemically induced
Middle Aged
Myocardial Infarction / prevention & control*
Warfarin / administration & dosage*,  adverse effects
Reg. No./Substance:
50-78-2/Aspirin; 81-81-2/Warfarin
Erratum In:
Am J Cardiol 1990 Jun 1;65(20):1410

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bladder cancer: detection, prevention, and therapeutics.
Next Document:  Prevention of left ventricular mural thrombus.